|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alberta Cancer Board |
|---|---|
| Information provided by: | Alberta Cancer Board |
| ClinicalTrials.gov Identifier: | NCT00310479 |
Purpose
We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will endeavor to prove this by having patients with prostate cancer pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery, the microscopic locations of cancer will be compared with the pre-operative images to assess how well the imaging technique succeeds.
| Condition | Intervention |
|---|---|
|
Prostate Cancer |
Device: Magnetic Resonance Spectroscopy (3Tesla) |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
| Official Title: | Clinico-Pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer |
| Estimated Enrollment: | 16 |
| Study Start Date: | June 2006 |
| Estimated Study Completion Date: | November 2006 |
The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites can be identified in correlation with clinically active tumor reserved on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR spectra of prostate cancer will allow for more detailed metabolic assessment with higher sensitivity, specificity and accuracy and publish results established from MR spectra using 1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the clinical wave of the future for cancer imaging, and if successful, will assume a very major role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat and novel therapeutics in the fight against prostate cancer.
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Matthew Parliament, MD | 780-432-8749 | matthewp@cancerboard.ab.ca |
| Canada, Alberta | |
| Cross Cancer Institute | Recruiting |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Contact: Paula Langenhoff, BHA 780-432-8909 paulalan@cancerboard.ab.ca | |
| Principal Investigator: Matthew Parliament, MD | |
| Principal Investigator: | Matthew Parliament, MD | Alberta Cancer Board |
More Information
| Study ID Numbers: | GU-6-0062 |
| Study First Received: | April 3, 2006 |
| Last Updated: | November 9, 2006 |
| ClinicalTrials.gov Identifier: | NCT00310479 History of Changes |
| Health Authority: | Canada: Health Canada |
|
Magnetic Resonance Imaging prostate cancer imaging 3T MRS functional imaging |
|
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
|
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
